The drug use
The optimal dose of the drug in sports is 100-300 mg per week. For convenience, the reception dose is divided into 2-3 pieces.
The medicine is not more than 6-8 weeks.
Trenbolone has a high content of androgens, it is necessary to create a body of relief. A marked increase in relief - not only affects the use of trenbolone acetate. It is also a potent anabolic that promotes muscle in a place near the iDianabolu testosterone level but without the same level of fluid delay. Such a description seems a bit exaggerated, since the lack of estrogenic activity reduces the drug's ability to promote muscle growth. While trenbolone is often recommended as a complement to the cycles of weight gain when drugs are used alone it is enough popular. As a result of its application more often moderate growth of muscle tissue, followed by an exceptional increase fat loss and relief it is observed.
Some bodybuilders and athletes use trenbolone esters for their muscle-building and otherwise performance-enhancing effects.  Such use is illegal in the United States and many other countries. The DEA classifies trenbolone and its esters as Schedule III controlled substances under the Controlled Substances Act .  Trenbolone is classified as a Schedule 4 drug in Canada  and a class C drug with no penalty for personal use or possession in the United Kingdom .  Use or possession of steroids without a prescription is a crime in Australia . 
Trenbolone acetate is a modified form of nandrolone.  The structure of trenbolone acetate is a 19-nor classification, which represents a structural change of the testosterone hormone. Trenbolone acetate lacks a carbon atom at the 19 position and carries a double bond at carbons 9 and 11. The position of these carbons slows its metabolism, which greatly increases its binding affinity to the AR, and inhibits it from undergoing aromatization into the corresponding estrogenic metabolite. Trenbolone acetate contains trenbolone modified with the addition of a carboxylic acid ester ( acetic acid ) at the 17β-hydroxyl group.  This facilitates the slow release of the AAS from the area of injection.